MNOV
MEDICINOVA INC
NASDAQ · Healthcare · Biotechnology · US
$3.32
−3.77%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.19
From 52W high−3.77%
Volume1.63M
Market cap$163.41M
P/E (TTM)—
P/S (TTM)177.5x
Div yield—
Key dataSep 18, 2026
Open
$3.19
From 52W high
−3.77%
Volume
1.63M
Market cap
$163.41M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.6x
P/E (TTM)
—
RSI (14)
94.6
MomentumView details →
1D Return
−3.77%
YTD Return
+174.81%
SummaryUpdated Jun 1, 2026
MediciNova, Inc. (NASDAQ:MNOV) is a biopharmaceutical company founded in 2000 and headquartered in La Jolla, California. The company went public in December 2006 and focuses on developing novel small molecule therapeutics for serious diseases with significant unmet medical needs. MediciNova operates as a clinical-stage biotechnology company with no marketed products, relying on its pipeline of drug candidates in various stages of development across multiple therapeutic areas including neurology, respiratory diseases, and oncology.
Similar companies
Latest newsMore news →
At 09:03 on September 18, 2026, Kikusui Electronics (6977) led special buy quotes with 7.17 billion yen in buy orders and zero sell orders, while newly listed TechnoClaf (622A) led special sell quotes with 220 million yen in sell orders.2d agoJapanese stocks rose on September 17, with Kubotek leading the Tokyo Stock Exchange Standard market gainers at a 29.6% increase.3d agoMediciNova Inc. announced the appointment of Yuichi Iwaki as President and Chief Executive Officer and Kazuko Matsuda as Chief Medical Officer, effective August 17, 2026, with compensation packages including base salaries and severance terms.32d ago